Zhengye Biotechnology Holding Ltd
ZYBT
Analytical Summary
Zhengye Biotechnology Holding Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.
3-Year Financial Trajectory
QuarterlyBullish Indicators
- No bullish signals detected.
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
- Profit Margin (%)Profit Margin (%) is in the bottom quartile
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ |
|---|---|---|---|
| Debt to Equity (x) |
0.30x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-50%)
|
0.30x
Good
Good
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-49%)
|
— |
| Net Debt (USD) | $10.68M | $9.29M | — |
Secondary lens
Benchmark Lens
Compare ZYBT against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ZYBT against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for ZYBT
No bullish signals detected
Operating Margin (%) is in the bottom quartile
Profit Margin (%) is in the bottom quartile
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How ZYBT compares to all companies
Peer Comparison
ZYBT vs similar peers
Compare ZYBT with peers
Stack ZYBT against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 3 quarters